The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin,FLT3/IDH/BCL2 inhibitors,and other therapies |
| |
| Authors: | Lauren Pommert Katherine Tarlock |
| |
| Affiliation: | 1.Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children''s Hospital Medical Center, Cincinnati, OH;2.Department of Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH;3.Division of Hematology and Oncology, Seattle Children''s Hospital, Seattle, WA;4.Department of Pediatrics, University of Washington School of Medicine, Seattle, WA;5.Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA |
| |
| Abstract: | Open in a separate window |
| |
| Keywords: | |
|
|
